newsletter masthead
March 29, 2019
Bowell, Brian
Brian J. Bolwell, MD
Chairman, Taussig Cancer Institute, Cleveland Clinic
Deputy Director for Cleveland Clinic, Case CCC
VeloSano is an unexpected success story. I remember when we first discussed launching a philanthropic bike ride. I was skeptical that it would amount to much. I was wrong. (I frequently say "I was wrong", or "I don't know." I highly recommend giving it a try). VeloSano not only brings in a lot of dollars designated for cancer research, it has grown into something that transcends the event itself. It's a community of people touched by cancer that wants to do something to contribute to research that might lead to scientific and clinical progress and even cures. The event itself transcends a feeling of celebration-it is a spiritual and emotional entity. It is certainly worth experiencing. 
For the past three years the Case Comprehensive Cancer Center (Case CCC) has had a team of riders all dedicated to the cause. Last year alone the Case CCC team raised over $70,000 in donations and sponsorship, and in return VeloSano gave $500,000 to the Case CCC to further the mission of collaborative scientific discovery. The Case CCC is once again using these funds to support the new and innovative ideas developed by our extraordinary researchers. Pilot grants will be awarded, in which we vet the most promising ideas and quickly get funding into the hands of researchers with the hope of changing the path of cancer.
Overall participation of the Case CCC in VeloSano has been modest. We'd love to see a larger presence this year to showcase the Case CCC and have a stronger visual display of our collaboration. The more that Case CCC participates, the more money we will collectively raise, and the more money will be available for pilot grants. Let's work together to increase the amount raised to allow for a potentially larger return in pilot funding!  
Participation is a pretty easy way to elevate funding for our cancer center. I strongly recommend that you consider participating in VeloSano. An additional benefit is that the supporters love hearing about our research efforts and getting to know our researchers. Being part of this community is worth experiencing, and you are able to meet a lot of kind-hearted people who want to help.

More about VeloSano and how to get involved
Team Case CCC page 
View last year's Case CCC VeloSano pilot awardees
Apply for VeloSano pilot funding
Using AI to Predict Response to Chemo
Pingfu FuA team of researchers, 
including Cancer Center members Anant Madbhushi, PhD and Pingfu Fu, PhD, published a paper in Artificial Intelligence in Radiology detailing their work on using radiomics to predict who will benefit from chemotherapy. 

The team developed novel AI approaches for interrogating the regions within and outside lung nodules on baseline CT scans to identify which lung cancer patients would respond to chemotherapy. The AI model had an accuracy of 77% in correctly predicting which of the patients would go on to have a favorable response versus not on an independent validation set of 73 patients.

This study was led by Mohammadhadi Khorrami, PhD candidate in the Case Western Reserve University (CWRU) Department of Biomedical Engineering and Monica Khunger, MD from the Department of Internal Medicine at Cleveland Clinic. Members of the  CWRU Center of Computational Imaging and Personalized Diagnostics and clinical investigators from Cleveland Clinic Taussig Cancer Institute also contributed.  more>
Chronicling How a Cancer Drug Works by Triggering the Immune System
Led by Robert Silverman, PhD, researchers at the Cleveland Clinic clarified how a drug (5-azacytidine, or AZA) commonly prescribed to treat myelodysplastic syndromes and acute myeloid leukemia causes cancer cell death. The work identifies several therapeutic targets that may assist the drug's already powerful ability to fight disease. As researchers continue to develop interest in engineering and training the body's cells to use "self" to fight cancer, the findings provide a more comprehensive understanding on how the drug's ability to prevent methylation and therefore increase expression of dsRNA to prevent the proliferation of cancer cells. more>
How You Can Benefit from Social Media Platforms
Navneet Majhail, MD recently spoke at the annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Frankfurt, Germany and shared some of his insights on why providers and investigators should leverage social media platforms such as Twitter. 

Check out his thoughts below and follow him on Twitter @BldCancerDoc.

A Twitter masterclass - how HCPs can benefit from social media platforms
Cancer Center Seminar Series: "HPV VLPs: Nature Nanoparticles for Cancer Prevention and Treatment"
Mar 29, 12p | WRB Auditorium

Join us today at noon in the Wolstein Research Building Auditorium to hear National Institutes of Health (NIH) Distinguished Investigator  John T. Schiller, PhD present, "HPV VLPs: Nature Nanoparticles for Cancer Prevention and Treatment." Dr. Schiller is part of the Center for Cancer Research at the National Cancer Institute (NCI). In his 35 years at the NCI, Dr. Schiller has studied various aspects of papillomavirus molecular biology, immunology and epidemiology. The laboratory headed by Dr. Schiller and Dr. Douglas R. Lowy led the discovery, characterization and clinical testing of virus-like particle (VLP) vaccines to prevent HPV infections that cause cervical and other cancers. Dr. Schiller's current interests include basic studies of papillomavirus virion assembly and infection, single does prophylactic HPV vaccines, therapeutic HPV vaccines and VLP-based vaccines, and therapies for other infectious diseases and cancers.

View a list of upcoming seminars>

The Seminar Series  will  be
available to view via live stream. While we highly encourage you to attend in person to interact with our speakers and receive CME credit, we understand that may not always be possible. Presentations will not be recorded for later viewing, but you may watch the seminar in real time and ask questions via chat.  Watch live at noon>
Book Your Room by April 3 for the Great Lakes Breast Cancer Research Symposium

Please be sure to book your room for the Great Lakes Breast Cancer Research Symposium on or before Wednesday, April 3! After April 3, the hotel cannot guarantee room availability or the negotiated group rate.  Book now>
Earn a $100 Fundraising Match for VeloSano on April 11!

Be one of the first 250 people to raise $100, 
all on Thursday, April 11, and VeloSano will match it! April 11 marks 100 days until "Bike to Cure" weekend. Register to join the Case CCC team and get ready:
  • Donations must be received on Thursday, April 11 between 12:00am - 11:59pm EDT
  • Individual Riders and Virtual Riders registered for VeloSano 6 (2019) are eligible
  • Only online donations made to participants' personal pages on are eligible
  • Team donations are not eligible
  • Matches will be applied on April 12
  • Individuals who qualify and receive the match will be notified via an email from Team VeloSano
Cancer Center Scientific Series
May 1, 8:30a | WRB Auditorium

We invite you to join us on Wednesday, May 1 as Case CCC researchers present findings from their pilot projects supported by the Research Innovation Fund. Researchers will offer an overview of their scientific discoveries and outlines of what comes next for their projects.

Breakfast will begin at 8:30am in the Cancer Center Conference Room, WRB 1-422D with presentations beginning at 9am in the auditorium, WRB 1-413.
The Case Comprehensive Cancer Center Scientific Series is a quarterly, extended conference featuring presentations by members who received pilot funding after competitive peer-review by the Cancer Center. 
Save the Date! Upcoming Case CCC Events

Case Comprehensive Cancer Center Annual Scientific Retreat
July 25-26, 2019
Additional information coming soon!

AI and Oncology: Advances, Decision-Making and Regulatory Considerations
October 23-24, 2019
Tinkham Veale University Center, CWRU campus
The Mark Foundation 2019 Emerging Leader Awards
LOI Deadline: May 10, 2019

The Mark Foundation Emerging Leader Awards provide grant support to early career investigators conducting high-impact, high-risk cancer research. The 3-year, $750,000 award is intended to support highly promising projects for which other sources of funding are not readily available or for a separate innovative endeavor that will allow the applicant to pursue a distinct and novel research direction.

  • PhD, MD or equivalent required
  • Applicant must be 3-8 years from the start of an independent faculty research appointment as of December 31, 2019
  • Projects must be centered on evidence-based laboratory, data and medical science.
  • Applicants must have multi-year independent funding that sustains the central studies of the laboratory
  • Applicants need not be US citizens but must be employed by a US nonprofit academic institution
Congressionally Directed Medical Research
Deadlines Vary

The Department of Defense's Congressionally  CDMRP logo Directed Medical Research Programs (CDMRP) recently released additional funding opportunities. Pre-application and application deadlines vary by award. Click each program below to view award announcements and application instructions.

FY19 Peer Reviewed Cancer Research Program (PRCRP)
  • Career Development Award
  • Horizon Award
  • Idea Award with Special Focus
  • Impact Award
  • Translational Team Science Award
FY19 Lung Cancer Research Program (LCRP)
  • Career Development Award
  • Idea Development Award
  • Investigator Initiated Translational Research Award
  • Translational Research Partnership Award
2019 Postdoctoral Fellowship in Understanding Dynamic and Multi-Scale Systems
Deadline: June 13, 2019

The James S. McDonnell Foundation (JSMF) 21st Century Understanding Dynamic and Multi-scale Systems Post-doctoral Fellowship program supports scholarship and research directed toward the discovery and refinement of theoretical and mathematical tools contributing to the continued development of the study of complex, adaptive, nonlinear systems. The program's emphasis is on the development and application of the theory and tools used in the study of complex research questions and not on particular fields of research per se. JSMF is also interested in projects attempting to apply complex systems approaches to coherently articulated questions where such approaches are not yet standard but could open up new paths to progress.

The JSMF Fellowship is a unique opportunity for students with an interest in and an aptitude for complexity science who are in the final stages of completing their PhD and looking to make a significant change in direction for their first postdoctoral fellowship (field of study, model organism, theory vs experimental, etc.) that will either be difficult or impossible without an external source of funding. The award provides $200,000 of support to be expended in no less than 2 and no more than 3 years. Read more>
First Immunotherapy Approved for Breast Cancer
Crossroads Today - Mar 14, 2019
The FDA has approved the first-ever combination of an immunotherapy drug plus chemotherapy for treating breast cancer. Cleveland Clinic oncologist and Case CCC member Jame Abraham, MD explains that the treatment is an option for some women diagnosed with metastatic triple-negative breast cancer.

5 ways Cleveland Clinic, Case Western Reserve University's new campus will change medical education - Mar 28, 2019
Take another look inside the $515 million collaborative health education campus on East 93rd Street and see how it will change how students going into health professions learn.
NIH BULLETIN - Notices and Funding Opportunities
Notice of Availability of Administrative Supplements for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndromE) Project (Administrative Supplement/ Clinical Trial Optional)

Notice of Correction to RFA-CA-19-007 "The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trial Required)

Notice of Intent to Publish: Funding Opportunity Announcement for Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

Requests for Applications
Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required)(RFA-CA-19-035)
Deadline: June 28, 2019

Deadlines: June 11, 2019; November 20, 2019

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)(RFA-CA-19-039)
Deadlines: June 11, 2019; November 20, 2019

Deadlines: June 11, 2019; November 20, 2019
Fri, Mar 29
AACR Annual Meeting 2019
Highlights from the Case CCC
Mar 29-April 3
Atlanta, GA

Cancer Center Seminar Series
John T. Schiller, PhD
NIH Distinguished Investigator
Center for Cancer Research
National Cancer Institute
"HPV VLPs: Nature Nanoparticles for Cancer Prevention and Treatment"
12p WRB Auditorium
Mon, April 1
Genomic Medicine Institute
Abby Bifano, PhD
Biological Safety Officer
Lerner Research Institute
Cleveland Clinic
Christine McDonald, PhD
IBC Chair
Lerner Research Institute
Cleveland Clinic
"Everything You've Always Wanted to Know About IBC Compliance, but Were Afraid to Ask"
12p NE1-205

Cancer Center Research Chalk Talk
1p WRB 3-136

Tumor Immunology and Immunotherapy Meeting
Suparna Mazumder, PhD
Cleveland Clinic
4p WRB 1-422D

Physiology and Biophysics Seminar
Carlos T. Moraes, PhD
University of Miami
"Developing Genetic Treatments for Mitochondrial DNA Diseases"
4p SOM E-501
Weds, April 3
Molecular Biology and Microbiology Virology Journal Club
12p WRT 206
Thurs, April 4
Developmental Therapeutics Journal Club
9a NE6-218

Molecular Biology and Microbiology Virology Journal Club
Ivelisse Resto Garay
Popkin Lab
1p SOM W203
Fri, April 5
Taussig Cancer Institute Grand Rounds
8a CA5-120

Cancer Center Seminar Series
William Grady, MD, AGAF
Assistant Professor, Pharmacology
Case Western Reserve University
"Mitochondrial Fission: Structure, Function and Cancer Implications"
12p WRB Auditorium
Mon, April 8
Genomic Medicine Institute International PTEN Symposium
Intercontinental Hotel & Conference Center

Shared Resources Directors Meeting
12p WRB 1-422D
Weds, April 10
Happy Hour for Team Case CCC VeloSano
4p Tavern of Little Italy

Molecular Biology and Microbiology Seminar
Angelica Cruz Lebron
Pathogen of the Month: "H pylori"
5p WRT 206
Thurs, April 11
Developmental Therapeutics Journal Club
9a N E 6-218

Molecular Biology and Microbiology Seminar
Claire Mazahery
Jeff McCausland
Levine Lab
1p SOM W203
Fri, April 12
UH Seidman Cancer Center Grand Rounds
8a Wearn 137

Taussig Cancer Institute Grand Rounds
8a CA5-120

Cancer Center Seminar Series 
Benjamin G. Neel, MD, PhD
Rodger C. Haggitt Professor of Medicine
Gastroenterology Division, University of Washington School of Medicine 
Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
" Age Related  Mechanisms of Colorectal Cancer Promotion"
12p WRB Auditorium

$5 Ice Cream Sundae Bar VeloSano Fundraiser for Team Case CCC
1-3p WRB Lobby

Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center